| Identification | Back Directory | [Name]
CNDAC | [CAS]
135598-68-4 | [Synonyms]
DFP-10917
2'-Cyano-2'-deoxy-1-(b-D-arabinofuranosyl)cytosine
2(1H)-Pyrimidinone, 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-
4-Amino-1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone | [Molecular Formula]
C10H12N4O4 | [MOL File]
135598-68-4.mol | [Molecular Weight]
252.23 |
| Chemical Properties | Back Directory | [Boiling point ]
596.9±60.0 °C(Predicted) | [density ]
1.75±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
12.78±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
CNDAC is a metabolite of the orally active agent Sapacitabine.html" class="link-product" target="_blank">Sapacitabine (HY-16445), and a nucleoside analog. CNDAC induces DNA damage and apoptosis[1][2]. | [Definition]
ChEBI: CNDAC is a pyrimidine 2'-deoxyribonucleoside that is 2'-deoxycytidine having a cyano group in the 2'-position. It is the active metabolite of the anti-cancer drug, sapacitabine which is currently in clinical development for the treatment of hematologic malignancies and solid tumors. It has a role as an antineoplastic agent, a drug metabolite and a DNA synthesis inhibitor. It is a pyrimidine 2'-deoxyribonucleoside and a nitrile. | [in vivo]
CNDAC (20mg/kg; i.p.; daily for 10 days) shows antitumor activity in mice[4]. | Animal Model: | CDF1 mice, P388 tumor model[4] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection, daily for 10 days | | Result: | Greatly increased the survival time and survival rate. |
| [References]
[1] Liu XJ, et al. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. hin J Cancer. 2012 Aug;31(8):373-80. DOI:10.5732/cjc.012.10077
[2] Jagan S, et al. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine. Adv Hematol. 2012;2012:727683. DOI:10.1155/2012/727683
[3] Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36. DOI:10.1038/sj.bjc.6603896
[4] Azuma A, et al. Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 1993 Dec 24;36(26):4183-9. DOI:10.1021/jm00078a006 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1701258/0_EN.htm |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|